Osteologie 2019; 28(01): 66
DOI: 10.1055/s-0039-1680013
Forum Junge Wissenschaft der DGO
Georg Thieme Verlag KG Stuttgart · New York

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment

E Tsourdi
1   Universitätsklinik Dresden Carl Gustav Carus, Medizinische Klinik III, Endokrinologie, Diabetes, und Metabolische Knochenerkrankungen, Dresden
,
P Makras
2   251 Hellenic Force & VA General Hospital, Department of Endocrinology and Diabetes, Athen
,
T Rachner
1   Universitätsklinik Dresden Carl Gustav Carus, Medizinische Klinik III, Endokrinologie, Diabetes, und Metabolische Knochenerkrankungen, Dresden
,
S Polyzos
3   Medical School, Aristotle University of Thessaloniki, First Department of Pharmacology, Thessaloniki
,
M Rauner
1   Universitätsklinik Dresden Carl Gustav Carus, Medizinische Klinik III, Endokrinologie, Diabetes, und Metabolische Knochenerkrankungen, Dresden
,
S Mandanas
4   424 General Military Hospital, 54638 Thessaloniki, Greece, Department of Endocrinology, Thessaloniki
,
A Anastasilakis
4   424 General Military Hospital, 54638 Thessaloniki, Greece, Department of Endocrinology, Thessaloniki
,
L Hofbauer
1   Universitätsklinik Dresden Carl Gustav Carus, Medizinische Klinik III, Endokrinologie, Diabetes, und Metabolische Knochenerkrankungen, Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
05 March 2019 (online)

 

Introduction:

Prior osteoporosis therapies may affect the skeletal response to denosumab. We compared the effect of denosumab (60 mg every 6 months for 12 months) on bone mineral density and bone metabolism parameters in postmenopausal women with low bone mass who were either treatment-naïve (n = 30), or previously treated either with zoledronic acid (n = 30), or teriparatide (n = 22).

Methods:

We assessed lumbar spine bone mineral density (BMD) and measured serum concentrations of the bone turnover markers pro-collagen type 1 N-terminal propeptide (PINP) and C-terminal-cross-linking telopeptide of type 1 collagen (CTX), as well as sclerostin, dickkopf-1 (Dkk-1), and myostatin.

Results:

Lumbar spine BMD increased equivalently in all three groups after 12 months of denosumab compared to baseline (p < 0.001). Serum PINP and CTX decreased significantly with denosumab in pre-treated women reaching the same nadir levels as in treatment-naïve patients (p < 0.001). Sclerostin and Dkk-1 concentrations were not statistically different between groups at all time points. Women pre-treated with teriparatide displayed lower baseline myostatin concentrations as compared to the other two groups (p < 0.001). Changes in lumbar spine BMD in teriparatide pre-treated women correlated with changes in bone turnover markers and myostatin.

Discussion:

Denosumab induced similar increases in lumbar spine BMD in treatment-naïve and pre-treated patients and suppressed serum PINP and CTX to the same levels regardless of prior treatments. In teriparatide pre-treated patients the magnitude of change in bone turnover markers is associated with BMD response.